ROCHE HLDG DR (RHO5 HM) stock market data APIs
€393.8297
0.1(0%)
as of March 4, 2026
Try our APIs with
free plan!
ROCHE HLDG DR Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for RHO5.HM.
Prev. Close
393.8297
Open
393.9311
High
393.9311
Low
393.7063
52 wk Range
235.4067-410.1
Market Cap
312 681 M
Dividends (Yield)
0.0415
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG DR data using free add-ons & libraries
Get ROCHE HLDG DR Fundamental Data
ROCHE HLDG DR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG DR News
New
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s pharmaceu...
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met its primary endpoint. Fenebrutinib is an experimental oral, c...
Roche’s Fenebrutinib MS Results Test Valuation And Growth Expectations
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Roche Holding (SWX:ROG) reported that its investigational MS treatment fenebrut...
Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial
The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis. Continue Reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
